CAS: 3569-99-1; N-(Hydroxymethyl)-3-Pyridinecarboxamide

该化合物是硝酸铵(niconamid)的衍生物,其成分为亚化物功能组的氮原子所附带的氢氧化硫组,其特征为白色和白外晶体外观,在水和各种有机溶剂中可溶解,使其具有多种用途,显示出与尼可丁酸和亚胺有关的特性,包括与细胞代谢和能源生产有关的生物化学途径的潜在作用.N-(Hydroxymothy)nicotinamide经常被研究其在皮肤护理配方方面的潜在好处,因为它能够加强皮肤水分作用,改善整个皮肤外观.此外,它可能对药理学研究产生影响,特别是在代谢紊乱和细胞信号方面.与许多化学物质一样,应参考安全数据,以了解其处理方式及其对健康和环境的潜在影响.

结构式图片

相似化合物

114-33-0 6265-73-2 583-08-4

物理性质

MSDS等安全信息

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号100-54-9 3-氰基吡啶 | CAS号50-00-0 甲醛 | CAS号98-92-0 烟酰胺 | CAS号50-00-0 甲醛 | CAS号98-92-0 烟酰胺 | CAS号100-54-9 3-氰基吡啶 | CAS号91026-38-9 N-[(2-hydroxyna...

合成工艺路线路线简述

    📜烟酰胺 反应生成 N-羟甲基烟酰胺
    参考文献:Cousse,H.;Mouzin,G.;Rieu,J.-P.;Delhon,A.
    标题:Cousse,H.;Mouzin,G.;Rieu,J.-P.;Delhon,A.

    海关参考信息

    专利信息


    专利号:WO-2023183781-A2
    优先权日:2022-03-20
    标 题:Legionaminic acid glycosyltransferases for chemoenzymatic synthesis of glycans and glycoconjugates

    专利号:US-4436912-A
    优先权日:1981-09-08
    标题:7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido cephalosporin antibiotics and intermediates therefor
    发明人：WHEELER WILLIAM J
    权利人:LILLY CO ELI
    摘要:Cephalosporin broad spectrum antibiotics possessing a 7 beta -[2-[(2-aminooxazol)-4-yl]-2-(substituted oximino]acetamido side chain and a variety of substituents at the 3-position of the cephalosporins are claimed. Also claimed are intermediates in the synthesis of the above cephalosporin antibiotics.

    专利号:US-2016311851-A1
    优先权日:2015-04-22
    标题 :Methods for the synthesis of ceragenins

    专利号:US-4430499-A
    优先权日:1981-09-08
    标题:7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido]cephalosporin antibiotics
    发明人：WHEELER WILLIAM J
    权利人:LILLY CO ELI
    摘要:Cephalosporin broad spectrum antibiotics possessing a 7 beta -[2-[(2-aminooxazol)-4-yl]-2-(substituted oximino)acetamido side chain and a variety of substituents at the 3-position of the cephalosporins are claimed. Also claimed are intermediates in the synthesis of the above cephalosorin antibiotics.

    专利号:US-8361516-B2
    优先权日:2006-08-03
    标 题:Composition comprising sarsasapogenin
    发明人：LINTNER KARL; MAS CHAMBERLIN CLAIRE
    权利人:SEDERMA SA; LINTNER KARL; MAS CHAMBERLIN CLAIRE
    摘要:The présent invention relates to a composition comprising sarsasapogenin or a plant extract containing it in order to improve the gêneral state of the skin and in particular to improve and/or embellish any part of the body showing a déficit in lipids. More particularly, the invention is directed to a cosmetic method to improve the figure, comprising the step of topically applying to the skin a cosmetic or dermopharmaceutical composition comprising sarsasapogenin to favour the expansion and/or the formation of the subcutaneous adipose tissue, and/or to favour the lipid synthesis in the epidermis.

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    [参考文献]: Zhang Hk, Et, Al. [参考文献]: Yao Xue Xue Bao. 1992; 27(8): 629-31.
    [参考文献]: H K Zhang, Et Al. [参考文献]: Yao Xue Xue Bao. 1992;27(8):629-31.

    合成参考文献


    参考文献:10.1038/ncb3255
    摘要:Lin R, Elf S, Shan C, Kang HB, Ji Q, Zhou L, Hitosugi T, Zhang L, Zhang S, Seo JH, Xie J, Tucker M, Gu TL, Sudderth J, Jiang L, Mitsche M, DeBerardinis RJ, Wu S, Li Y, Mao H, Chen PR, Wang D, Chen GZ, Hurwitz SJ, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Lei Q, Brat DJ, Ye K, Boggon TJ, He C, Kang S, Fan J, Chen J. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol. 2015 Nov;17(11):1484–96.
    摘要:Archiv der Pharmazie, 305(427), 1972 []
    摘要:Acta Poloniae Pharmaceutica. For English translation, see APPFAR., 17(73), 1960
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知